61 Bower M, McCall-Peat N, Ryan N et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104: 2943–2946. 62 Mead GM, Barrans SL, Qian W
et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248–2260. 63 Mead GM, Sydes MR, Walewski J et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264–1274. 64 Magrath I, Adde M, Shad A et al. Adults and children with small non-cleaved-cell lymphoma have a similar
MAPK Inhibitor Library datasheet excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925–934. 65 Wang ES, Straus DJ, Teruya-Feldstein J et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, selleck chemicals llc high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98: 1196–1205. 66 Cortes J, Thomas D, Rios A et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492–1499. 67 Oriol A, Ribera JM, Esteve J et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003; 88: 445–453. 68 Montoto S, Wilson J, Shaw K et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS 2010; 24: 851–856. 69 Mohamedbhai SG, Sibson K, Marafioti T et al. Rituximab in combination with CODOX-M/IVAC:
a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Br J Haematol 2011; 152: 175–181. 70 Oriol A, Ribera JM, Bergua J et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. GPX6 Cancer 2008; 113: 117–125. 71 Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma(BL): Preliminary results of a prospective multicenter phase ii trial of the AIDS Malignancy Consortium (AMC). Blood 2009; 114: Abstract 3673. 72 Barnes JA, Lacasce AS, Feng Y et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol 2011; 22: 1859–1864. 73 Ribera JM, Garcia O, Grande C et al.